コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 e events, which were graded according to the Common Terminology Criteria for Adverse Events.
2 aluated with the National Cancer Institute's Common Terminology Criteria for Adverse Events.
3 ty was assessed and handled according to the Common Terminology Criteria for Adverse Events.
4 are reported using National Cancer Institute Common Terminology Criteria for Adverse Events.
5 sessment of Cancer Therapy questionnaire and Common Terminology Criteria for Adverse Events.
6 as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events.
7 as documented prospectively and according to Common Terminology Criteria for Adverse Events 4.0 crite
8 gher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at le
9 matologic and gastrointestinal toxicities by Common Terminology Criteria for Adverse Events and perip
11 l, overall survival, safety as determined by Common Terminology Criteria for Adverse Events criteria,
12 xicities never exceeded grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE v2
14 e usually reported National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) a
17 daptation of the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) v
18 and comparing it with the currently utilized Common Terminology Criteria for Adverse Events (CTCAE).
21 lic and diastolic blood pressure not meeting Common Terminology Criteria for Adverse Events (CTCAEv3)
22 o malaise, headache, and moderate dizziness (Common Terminology Criteria for Adverse Events grade 2).
23 e overall risk for National Cancer Institute-Common Terminology Criteria for Adverse Events grade 3 A
24 ars from diagnosis were classified using the Common Terminology Criteria for Adverse Events, grades 3
25 dverse events was recorded and graded using "Common Terminology Criteria for adverse events in Trials
26 n-based therapy by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCA
27 d a patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCA
28 pathy by using the National Cancer Institute Common Terminology Criteria for Adverse Events scale or
32 according to the National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0) or
33 ic effects were prospectively assigned using Common Terminology Criteria for Adverse Events, v3.0.
34 cardiac events were reviewed and graded per Common Terminology Criteria for Adverse Events (v4.03).
36 t-reported symptoms were collected using the Common Terminology Criteria for Adverse Events version 3
37 s) were recorded and graded according to the Common Terminology Criteria for Adverse Events version 3
38 ed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events Version 4
39 vents according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4
41 d according to the National Cancer Institute Common Terminology Criteria for adverse events version 4
42 ues, and vital signs graded according to the Common Terminology Criteria for Adverse Events version 4
43 adverse events were graded according to the Common Terminology Criteria for Adverse Events version 4
44 defined as grade 3 to 4 chronic conditions (Common Terminology Criteria for Adverse Events version 4
45 ssed by Immune-related Response Criteria and Common Terminology Criteria for Adverse Events version 4
46 cessful hair preservation assessed using the Common Terminology Criteria for Adverse Events version 4
47 y according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version
48 ow-up questionnaires and graded according to Common Terminology Criteria for Adverse Events (version
49 Acute and late reactions were scored using Common Terminology Criteria for Adverse Events (version
52 , or grade 3 or 4 nonhematologic toxicity by Common Terminology Criteria for Adverse Events (version
53 roughout follow-up and reported according to Common Terminology Criteria for Adverse Events (version
54 al failure, distant metastasis, and selected Common Terminology Criteria for Adverse Events (version
55 d to a grade 3 event, as determined with the Common Terminology Criteria for Adverse Events (version
56 te Common Toxicity Criteria [version 2.0] or Common Terminology Criteria for Adverse Events [version
57 ssessed with the National Cancer Institute's Common Terminology Criteria for Adverse Events, version
58 ing Association Ototoxicity Criteria (ASHA), Common Terminology Criteria for Adverse Events, version
59 xicity grades were reported according to the Common Terminology Criteria for Adverse Events, version
60 h medical examination and coded according to Common Terminology Criteria for Adverse Events, Version
63 guage-Hearing Association; Brock; Chang; and Common Terminology Criteria for Adverse Events, version
64 xic events after treatment (according to the Common Terminology Criteria for Adverse Events, version
65 Adverse events were graded according to the Common Terminology Criteria for Adverse Events, version
66 assigned to each health condition using the Common Terminology Criteria for Adverse Events, Version
67 l acute toxicity was scored according to the Common Terminology Criteria for Adverse Events, version
68 d according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version
69 patients were followed and graded using the Common Terminology Criteria for Adverse Events, version
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。